Name: Artificial Intelligence for Multi-Omics Analysis Part B: Volume 222 (en Inglés)
SKU: 66860221
Price: 165330.00 CLP
Availability: InStock
Author: Teplow, David B.; Singh, Vijai; Saha, Sudipto
ISBN: 9780443413490

portada Artificial Intelligence for Multi-Omics Analysis Part B: Volume 222 (en Inglés)

Artificial Intelligence for Multi-Omics Analysis Part B: Volume 222 (en Inglés)

Formato

Libro Físico

Editorial

Academic Press

Autor

Teplow, David B.; Singh, Vijai; Saha, Sudipto

Idioma

Inglés

N° páginas

300

Encuadernación

Tapa Dura

ISBN13

9780443413490

Artificial Intelligence for Multi-Omics Analysis Part B: Volume 222 (en Inglés)

Teplow, David B.; Singh, Vijai; Saha, Sudipto (Autor) · Academic Press · Tapa Dura

Libro Nuevo Importado

Envío: 17 a 22 días háb.

$ 300.600$ 165.330

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 165.330

Llega entre el 24 Sep y el 01 Oct a Santiago, Región Metropolitana. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Artificial Intelligence for Multi-Omics Analysis Part B: Volume 222 (en Inglés)"

Artificial Intelligence for Multi-omics Analysis Part B, Volume 222 in the Progress in Molecular Biology and Translational Science series, highlights recent advances, with this new volume presenting chapters on a variety of topics, including Artificial Intelligence in multi-omics analysis of small molecule drug discovery, AI in multi-omics analysis in antimicrobial resistance, Artificial Intelligence and multi-Omics Approach in Vaccine Development, Artificial Intelligence in multi-omics Analysis of heart diseases, Artificial Intelligence in multi-omics Analysis of Kidney Diseases, Artificial Intelligence in multi-omics Analysis of Gastrointestinal Diseases, AI in multi-omics analysis in Stem cell research, and AI in multi-omics analysis in cancer, and more. Additional sections cover AI in multi-omics analysis in obstructive lung diseases, AI in multi-omics analysis in neurodiseases, AI in multi-omics analysis in autoimmune diseases, AI in multi-omics analysis of liver diseases, AI in multi-omics analysis of COVID-19 patient data, and AI in multi-omics analysis of Type 2 diabetes.